All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Eftilagimod Alpha,Avelumab
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2020
Details:
41.7% of patients showed a Partial Response to the combination therapy of eftilagimod alpha and avelumab. Encouraging early anti-tumour activity signals in a variety of cancer indications not typically sensitive to immune checkpoint inhibitor (ICI) therapy.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Paxalisib,Radiation therapy
Therapeutic Area: Oncology Product Name: GDC-0084
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2020
Details:
Food and Drug Administration has granted Orphan Drug Designation to Kazia’s paxalisib (formerly GDC-0084) for the treatment of malignant glioma, which includes Diffuse Intrinsic Pontine Glioma (DIPG), a rare and highly aggressive childhood brain cancer.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Paxalisib,Radiation therapy
Therapeutic Area: Oncology Product Name: GDC-0084
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 07, 2020
Details:
With RPDD granted, Kazia may now be eligible to receive a ‘rare pediatric disease priority review voucher’ (PRV) if paxalisib is approved for DIPG.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Idronoxil
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2020
Details:
The posters addressed how NOX66 may improve treatment responses in men with mCRPC and also its contribution to restoring sensitivity to apoptosis and potentially modulating the immune microenvironment of nasopharyngeal carcinoma (NPC).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Eftilagimod Alpha,Avelumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2020
Details:
Last patient has been enrolled and safely dosed for the second cohort of the INSIGHT-004 Phase I clinical trial evaluating combination of eftilagimod alpha with a standard dose of avelumab.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Eftilagimod Alpha,Paclitaxel
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 19, 2020
Details:
Last patient enrolled and safely dosed, completing patient recruitment for EOC Pharma’s phase I study in metastatic breast cancer (MBC).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Idronoxil
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: GenesisCare
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 18, 2020
Details:
The alliance formalises a program under which Noxopharm has been making Veyonda® available through GenesisCare as an adjunctive therapy with 177Lu-PSMA therapy for mCRPC patientsin Australia.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
